British pharmaceutical leader Indivior Plc announced this week its new drug application (NDA) to the U.S. Food and Drug Administration for its drug treating opioid use disorder (OUD). The drug, RBD-6000 acts as a monthly injectable opioid which in conjunction with counseling and psychological support aims to drastically reduce and eliminate opioid reliance in adults. An estimated 1.9 million Americans suffer from opioid use disorder. Read the full press release here.